{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:38:54Z","timestamp":1785418734042,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,20]]},"DOI":"10.7759\/cureus.37891","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:46:58Z","timestamp":1682012818000},"source":"Crossref","is-referenced-by-count":2,"title":["Fatal Cryptococcal Meningitis in a Patient With Chronic Lymphocytic Leukemia Treated With Ibrutinib"],"prefix":"10.7759","author":[{"given":"Hari","family":"Oumayma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El Mehdi","family":"Mahtat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawa","family":"Moussa Bouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Elmaaroufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Doghmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.04.008","article-title":"Chronic lymphocytic leukemia","volume":"64","author":"Ghia P","year":"2007","unstructured":"Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2007, 64:234-46. 10.1016\/j.critrevonc.2007.04.008","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd JC","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, et al.. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013, 369:32-42. 10.1056\/NEJMoa1215637","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger JA","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al.. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015, 373:2425-37. 10.1056\/NEJMoa1509388","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham R","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, et al.. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017, 17:873-81. 10.1016\/S1473-3099(17)30243-8","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.167","article-title":"Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy","volume":"13","author":"Williamson PR","year":"2017","unstructured":"Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A, Harrison TS. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol. 2017, 13:13-24. 10.1038\/nrneurol.2016.167","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22094","article-title":"The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia","volume":"107","author":"Francis S","year":"2006","unstructured":"Francis S, Karanth M, Pratt G, et al.. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006, 107:1023-33. 10.1002\/cncr.22094","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.12.013","article-title":"Infectious complications of chronic lymphocytic leukemia","volume":"33","author":"Wadhwa PD","year":"2006","unstructured":"Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006, 33:240-9. 10.1053\/j.seminoncol.2005.12.013","journal-title":"Semin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","volume":"2008","author":"Dearden C","year":"2008","unstructured":"Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008, 2008:450-6. 10.1182\/asheducation-2008.1.450","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani RH","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, et al.. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013, 31:88-94. 10.1200\/JCO.2012.42.7906","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang ML","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al.. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013, 369:507-16. 10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien S","year":"2014","unstructured":"O'Brien S, Furman RR, Coutre SE, et al.. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol. 2014, 15:48-58. 10.1016\/S1470-2045(13)70513-8","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer R","year":"2019","unstructured":"Ruchlemer R, Ben-Ami R, Bar-Meir M, et al.. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study. Mycoses. 2019, 62:1140-7. 10.1111\/myc.13001","journal-title":"Mycoses"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4642831","article-title":"Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib","volume":"2016","author":"Okamoto K","year":"2016","unstructured":"Okamoto K, Proia LA, Demarais PL. Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis. 2016, 2016:4642831. 10.1155\/2016\/4642831","journal-title":"Case Rep Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217752078","article-title":"Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia","volume":"25","author":"Stankowicz M","year":"2019","unstructured":"Stankowicz M, Banaszynski M, Crawford R. Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia. J Oncol Pharm Pract. 2019, 25:710-4. 10.1177\/1078155217752078","journal-title":"J Oncol Pharm Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw261","article-title":"Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib","volume":"4","author":"Messina JA","year":"2017","unstructured":"Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. Open Forum Infect Dis. 2017, 4:ofw261. 10.1093\/ofid\/ofw261","journal-title":"Open Forum Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1508622","article-title":"Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?","volume":"20","author":"Abid MB","year":"2019","unstructured":"Abid MB, Stromich J, Gundacker ND. Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?. Cancer Biol Ther. 2019, 20:138-40. 10.1080\/15384047.2018.1508622","journal-title":"Cancer Biol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis MS","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, et al.. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017, 31:833-43.e5. 10.1016\/j.ccell.2017.04.012","journal-title":"Cancer Cell"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3546-3","article-title":"Ibrutinib brain distribution: a preclinical study","volume":"81","author":"Goldwirt L","year":"2018","unstructured":"Goldwirt L, Beccaria K, Ple A, Sauvageon H, Mourah S. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol. 2018, 81:783-9. 10.1007\/s00280-018-3546-3","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/151146-fatal-cryptococcal-meningitis-in-a-patient-with-chronic-lymphocytic-leukemia-treated-with-ibrutinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:55Z","timestamp":1707508795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/151146-fatal-cryptococcal-meningitis-in-a-patient-with-chronic-lymphocytic-leukemia-treated-with-ibrutinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.37891","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}